Literature DB >> 24476439

Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer.

Leonard B Saltz, Peter B Bach.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24476439     DOI： 10.1056/NEJMc1314761

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

1.  Porphyrin-lipid stabilized paclitaxel nanoemulsion for combined photodynamic therapy and chemotherapy.

Authors:  Enling Chang; Jiachuan Bu; Lili Ding; Jenny W H Lou; Michael S Valic; Miffy H Y Cheng; Véronique Rosilio; Juan Chen; Gang Zheng
Journal:  J Nanobiotechnology       Date:  2021-05-25       Impact factor: 10.435

2.  PRMT1 promotes pancreatic cancer growth and predicts poor prognosis.

Authors:  Chao Song; Tianwei Chen; Lan He; Ning Ma; Jian-Ang Li; Ye-Fei Rong; Yuan Fang; Mengmeng Liu; Dong Xie; Wenhui Lou
Journal:  Cell Oncol (Dordr)       Date:  2019-09-13       Impact factor: 6.730

Review 3.  Quantitative phenotypic and pathway profiling guides rational drug combination strategies.

Authors:  John C Dawson; Neil O Carragher
Journal:  Front Pharmacol       Date:  2014-05-28       Impact factor: 5.810

4.  Response to Drs Von Hoff and Renschler.

Authors:  Daniel H Ahn; Tanios Bekaii-Saab
Journal:  Ther Adv Med Oncol       Date:  2017-05-30       Impact factor: 8.168

Review 5.  Combination therapeutics in complex diseases.

Authors:  Bing He; Cheng Lu; Guang Zheng; Xiaojuan He; Maolin Wang; Gao Chen; Ge Zhang; Aiping Lu
Journal:  J Cell Mol Med       Date:  2016-09-07       Impact factor: 5.310

6.  Redox-responsive nanoplatform for codelivery of miR-519c and gemcitabine for pancreatic cancer therapy.

Authors:  Xiaofei Xin; Virender Kumar; Feng Lin; Vinod Kumar; Rajan Bhattarai; Vijaya R Bhatt; Chalet Tan; Ram I Mahato
Journal:  Sci Adv       Date:  2020-11-11       Impact factor: 14.136
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.